مباشر

Endpoints NewsGoHealth files for bankruptcy, as Medicare Advantage insurers pull back AgilentHow Investors May Respond To Agilent Technologies (A) Expanding AI-Enabled Lab Solutions And Oncology Diagnostics - simplywall.st BioPharma DiveTango data add to growing momentum for pancreatic cancer drugs Thermo FisherThermo Fisher Scientific Introduces New Mass Spectrometry Platforms and AI Software - Clinical Lab Products BioPharma DiveIncyte to buy blood disorder drug in possibly $2B deal FierceBiotechClinical-stage cancer biotech Treeline sees path to public markets via reverse merger FierceBiotechADA: Dexcom CGM shows benefit in non-insulin diabetes patients BioPharma DiveJ&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B Endpoints NewsTreeline to go public via reverse merger with Standard BioTools Roche MediaThis Biotech Stock Is Popping 10% on $2.3 Billion Roche Deal for Blood Cancer Drug - Barron's BioPharma DiveADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option FierceBiotechResmed snaps up Noctrix Health in $340M sleep tech deal

Endpoints News ٨ يونيو ٢٠٢٦

Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs

Cavalry Biosciences, the first biotech out of incubator and investor Jupiter Bioventures, is working on a $75 million Series B to bring its first two drug candi...

Cavalry Biosciences, the first biotech out of incubator and investor Jupiter Bioventures, is working on a $75 million Series B to bring its first two drug candidates into clinical testing, CEO Preston Klassen told Endpoints ...